The inhibitory receptor Siglec-G controls the severity of chronic lymphocytic leukemia

EMBO Rep. 2023 Aug 3;24(8):e56420. doi: 10.15252/embr.202256420. Epub 2023 Jul 10.

Abstract

Chronic Lymphocytic Leukemia (CLL) is the most common leukemia in adults in the Western world. B cell receptor (BCR) signaling is known to be crucial for the pathogenesis and maintenance of CLL cells which develop from mature CD5+ B cells. BCR signaling is regulated by the inhibitory co-receptor Siglec-G and Siglec-G-deficient mice have an enlarged CD5+ B1a cell population. Here, we determine how Siglec-G expression influences the severity of CLL. Our results show that Siglec-G deficiency leads to earlier onset and more severe course of the CLL-like disease in the murine Eμ-TCL1 model. In contrast, mice overexpressing Siglec-G on the B cell surface are almost completely protected from developing CLL-like disease. Furthermore, we observe a downmodulation of the human ortholog Siglec-10 from the surface of human CLL cells. These results demonstrate a critical role for Siglec-G in disease progression in mice, and suggest that a similar mechanism for Siglec-10 in human CLL may exist.

Keywords: BCR signaling; CLL; Siglec-10; Siglec-G overexpressing mice; Siglecs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • B-Lymphocytes / metabolism
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell* / genetics
  • Leukemia, Lymphocytic, Chronic, B-Cell* / metabolism
  • Leukemia, Lymphocytic, Chronic, B-Cell* / pathology
  • Mice
  • Mice, Transgenic
  • Proto-Oncogene Proteins
  • Receptors, Antigen, B-Cell / genetics
  • Sialic Acid Binding Immunoglobulin-like Lectins / genetics

Substances

  • Sialic Acid Binding Immunoglobulin-like Lectins
  • Proto-Oncogene Proteins
  • Receptors, Antigen, B-Cell

Associated data

  • GEO/GSE227678